Form 8-K - Current report:
SEC Accession No. 0001628280-17-000870
Filing Date
2017-02-03
Accepted
2017-02-03 17:00:53
Documents
5
Period of Report
2017-02-03
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K - ACETADOTE IP UPDATE a8k-acetadoteipupdate.htm 8-K 18799
2 EXHIBIT 99.1 - PRESS RELEASE - ACETADOTE UPDATE pressrelease-acetadoteupda.htm EX-99.1 15395
3 EXHIBIT 99.2 UPDATED RISK DISCLOSURE updatedriskfactors.htm EX-99.2 16292
4 cumberlanda02.gif GRAPHIC 10657
5 cumberlanda08.jpg GRAPHIC 96793
  Complete submission text file 0001628280-17-000870.txt   199678
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 17572860
SIC: 2834 Pharmaceutical Preparations